Julia A. Gaebler, PhD

Julia has accumulated over 20 years of experience in global pricing, market access, health economics, health policy and health services research in both the biopharma industry and academic research.

A mathematical modeler by training, she leads Health Advances’ Market Access and Policy Strategy Practice, serving biopharma, medtech, diagnostics, and digital health clients.

Work Experience

Immediately prior to joining Health Advances, Julia worked at Biogen as Senior Director, Global Medical Outcomes Strategy where she provided strategic leadership and technical health outcomes expertise to ensure that medical product strategies and tactics anticipated the evolving demands of the global payer landscape. At Biogen she was also Director, Global Market Access where she built and managed a team of Health Economics and Outcomes Researchers (HEOR) responsible for payer value evidence development for the Company’s late stage development products. In that capacity Julia led the global reimbursement and market access launches for TECFIDERA and FAMPYRA for Multiple Sclerosis. Julia has also held related positions at Amylin Pharmaceuticals, Hoffmann-La Roche, and the RAND Corporation where she supported payer and ‘Real World Evidence’ development for Phase II/III products in Diabetes, Obesity, HIV/AIDs and Hepatitis.

Education

Julia holds a Doctorate in Health Policy and Decision Analysis from Harvard University, a Masters in International Economics from Johns Hopkins University, and a BA from the University of Pennsylvania. She has held Adjunct Faculty positions at UCSD Division of Global Public Health and at the RAND Corporation and has published many articles on health technology assessment in journals such as Nature, Journal of Vascular Surgery, Health Services Research, Diabetes Medicine, and Plos Medicine. Julia is an Independent Director at Atlas5D.